New article discusses about modifications to breast cancer screening recommendations

NewsGuard 100/100 Score

A new article discusses the evidentiary support for the recent changes made by the American Cancer Society in its recommendations for breast cancer screening. In addition to modifying the suggested ages for annual and biannual mammography, the new recommendations also focus on patient preference in decision making.

The authors discuss the subtle but very important difference between the sensitivity and false positive rates for mammography. Among asymptomatic women, even though approximately 84% of breast cancers are detected by mammography, approximately 95% of all positive mammograms are false positives. The authors note that the emphasis on patient involvement in making health decisions could be problematic due to the difficulty patients may have in understanding this technical distinction.

"Our goal was to caution asymptomatic women that positive mammograms are vastly more likely to be false positives than actual evidence of cancer," said Dr. William Skorupski, co-author of the Significance article. "For most women, a false positive mammogram is about 19 times more likely than a true positive," added co-author Dr. Howard Wainer.

Source: Wiley


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer